Form 4: Monopar Therapeutics COO Andrew Cittadine Reports Stock Transactions
SEC Form 4 Filing
Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reports the acquisition and disposal of common stock and restricted stock units related to vesting.
Summary
- On March 31, 2024, Andrew Cittadine, the Chief Operating Officer of Monopar Therapeutics, reported transactions involving the company's stock.
- These transactions included the acquisition of 8,952 shares of common stock upon the vesting and settlement of restricted stock units.
- Additionally, 3,098 shares were withheld by the issuer to cover withholding taxes due upon the vesting of these units at a price of $0.681.
- Following these transactions, Cittadine directly owns 57,624 shares of Monopar Therapeutics common stock.
- The reported transactions also involve restricted stock units (RSUs) granted on February 2, 2022, and February 1, 2023, which vest in installments until December 31, 2025, and December 31, 2026, respectively.
- After the reported transactions, Cittadine directly owns 82,223 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information about ownership changes.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock. It's a standard practice for publicly traded companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 02/02/2022 | Reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. |
| 02/01/2023 | Reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. |
| 03/31/2024 | Date of stock transactions: acquisition of 8,952 shares via RSU vesting and disposal of 3,098 shares for tax withholding. |
| 04/02/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.